A solution for moisture-sensitive actives, focusing on Sitagliptin
Given that diabetes affects millions of individuals worldwide, it is critical to concentrate on medicine and treatment now more than ever. With 10 million Americans receiving prescriptions for Sitagliptin as a medication, it has proven to be both popular and beneficial for patients.
IMCD’s experts at the Pharmaceutical Technical Centre in Mumbai recently conducted a study to develop a solution for moisture-sensitive actives, focusing on Sitagliptin. The main aim was understanding Sitagliptin and other components to find an efficient, stable, and affordable solution.
We sat down with Prajal Pandhare, IMCD India’s Assistant Manager for Application Development, to discuss why Sitagliptin was chosen for the case study, the results, and the biggest challenges.
Why did you choose Sitagliptin for this study?
What were your biggest challenges ?
How can this help Sitagliptin manufacturers?
What are you particularly proud of as an outcome?